PITTSBURGH--(BUSINESS WIRE)--Cellumen, Inc., a discovery and early safety assessment company, today announced that its in vitro Rat Hepatocyte Early Safety Assessment Panel provides increased predictivity for human drug induced liver injury (DILI) equivalent to that of a recently published panel comprised of human hepatocytes. The implications of this study have a significant impact on cost and throughput for in vitro human DILI predictive solutions.
